TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.